Literature DB >> 19952871

PharmGKB very important pharmacogene: SLCO1B1.

Connie Oshiro1, Lara Mangravite, Teri Klein, Russ Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19952871      PMCID： PMC3086841          DOI： 10.1097/FPC.0b013e328333b99c

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  70 in total

1.  Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Biochemistry       Date:  2008-08-09       Impact factor: 3.162

2.  Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.

Authors:  Y Cui; J König; I Leier; U Buchholz; D Keppler
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

3.  Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.

Authors:  A Kalliokoski; J T Backman; K J Kurkinen; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

4.  Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.

Authors:  Hiroshi Takane; Katsuyuki Kawamoto; Tomohiro Sasaki; Kuniaki Moriki; Kazuyo Moriki; Hiroya Kitano; Shun Higuchi; Kenji Otsubo; Ichiro Ieiri
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-08       Impact factor: 3.333

5.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

Authors:  Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

6.  Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

Authors:  Philippe Couvert; Philippe Giral; Sylvie Dejager; Jessie Gu; Thierry Huby; M John Chapman; Eric Bruckert; Alain Carrié
Journal:  Pharmacogenomics       Date:  2008-09       Impact factor: 2.533

7.  Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism.

Authors:  Wendy M van der Deure; Edith C H Friesema; Frank Jan de Jong; Yolanda B de Rijke; Frank H de Jong; André G Uitterlinden; Monique M B Breteler; Robin P Peeters; Theo J Visser
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

8.  Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore.

Authors:  Woon Fei Ho; Seok Hwee Koo; Jie Yin Yee; Edmund Jon Deoon Lee
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

9.  Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

Authors:  Ji-Youn Han; Hyeong-Seok Lim; Yong Hoon Park; Sung Young Lee; Jin Soo Lee
Journal:  Lung Cancer       Date:  2008-01-24       Impact factor: 5.705

10.  Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism.

Authors:  Suttasinee Suwannakul; Ichiro Ieiri; Miyuki Kimura; Kiyoshi Kawabata; Hiroyuki Kusuhara; Takeshi Hirota; Shin Irie; Yuichi Sugiyama; Shun Higuchi
Journal:  J Hum Genet       Date:  2008-07-19       Impact factor: 3.172
View more
  23 in total

1.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

2.  Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.

Authors:  Mona F Shabana; Amal A Mishriki; Marianne Samir M Issac; Sameh W G Bakhoum
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

3.  Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.

Authors:  Xinyan Zhang; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Gene Morse; Robin DiFrancesco; Carrie Dykes; Hongyu Jiang; David W Haas
Journal:  Ther Drug Monit       Date:  2013-04       Impact factor: 3.681

4.  Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.

Authors:  Marco Ferrari; Luigina Guasti; Andrea Maresca; Mauro Mirabile; Sara Contini; Anna Maria Grandi; Franca Marino; Marco Cosentino
Journal:  Eur J Clin Pharmacol       Date:  2014-03-06       Impact factor: 2.953

5.  The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.

Authors:  Bodine P S Belderbos; Mirjam de With; Rajbir K Singh; Bram C Agema; Samira El Bouazzaoui; Esther Oomen-de Hoop; Ronald de Wit; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-01       Impact factor: 3.333

6.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.

Authors:  Mikael Kozyra; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  Genet Med       Date:  2016-04-21       Impact factor: 8.822

7.  Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes.

Authors:  Adam Y Ye; Qing-Rong Liu; Chuan-Yun Li; Min Zhao; Hong Qu
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

Review 8.  Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.

Authors:  William J Canestaro; Melissa A Austin; Kenneth E Thummel
Journal:  Genet Med       Date:  2014-05-08       Impact factor: 8.822

Review 9.  [Pharmacogenetics: what about Morocco?].

Authors:  Meryem Janati Idrissi; Karim Ouldim; Afaf Amarti; Mohamed El Hassouni; Youssef Khabbal
Journal:  Pan Afr Med J       Date:  2013-04-10

10.  Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.

Authors:  Agnes Nagy; Csilla Sipeky; Renata Szalai; Bela Imre Melegh; Petra Matyas; Alma Ganczer; Kalman Toth; Bela Melegh
Journal:  BMC Genet       Date:  2015-09-03       Impact factor: 2.797
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.